Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma

NAActive, not recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

August 28, 2015

Primary Completion Date

August 28, 2026

Study Completion Date

August 28, 2027

Conditions
LymphadenopathyStage I Testicular SeminomaStage II Testicular Seminoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Retroperitoneal Lymph Node Dissection

Undergo RPLND

Trial Locations (14)

21205

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

30322

Emory University, Atlanta

46202

Indiana University, Indianapolis

55905

Mayo Clinic, Rochester

60637

University of Chicago Medical Center, Chicago

73104

Stephenson Cancer Center, University of Oklahoma, Oklahoma City

80045

University of Colorado Hospital - Aurora, Aurora

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

92350

Loma Linda University Medical Center, Loma Linda

94143

University of California, San Francisco, San Francisco

94305

Stanford University Hospitals & Clinics, Stanford

98431

Madigan Army Medical Center, Tacoma

08903-2681

Rutgers Cancer Institute of New Jersey, New Brunswick

75390-9110

UTSouthwestern Medical Center, Dallas

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER

NCT02537548 - Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma | Biotech Hunter | Biotech Hunter